Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its position in Canadian Imperial Bank of Commerce (NYSE:CM) (TSE:CM) by 54.3% in the first quarter, HoldingsChannel reports. The firm owned 911,300 shares of the bank’s stock after buying an additional 320,800 shares during the quarter. Canadian Imperial Bank of Commerce comprises approximately 1.0% of Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s investment portfolio, making the stock its 19th largest position. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s holdings in Canadian Imperial Bank of Commerce were worth $103,633,000 as of its most recent filing with the Securities and Exchange Commission.
Hot Canadian Stocks To Watch For 2019: ABAXIS Inc.(ABAX)
Advisors' Opinion:- [By Lisa Levin]
Breaking news
Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis, Inc. (NASDAQ: ABAX) for $83 per share in cash. Boot Barn Holdings Inc (NYSE: BOOT) reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance. CELYAD SA/ADR (NASDAQ: CYAD) reported launch of 1.8 million share offering. Verastem Inc (NASDAQ: VSTM) shares dropped 12 percent in pre-market trading after announcing a $35 million common stock offering. - [By Shane Hupp]
Abaxis Inc (NASDAQ:ABAX) has received a consensus recommendation of “Hold” from the thirteen brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $67.00.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Abaxis (ABAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Lisa Levin]
Abaxis, Inc. (NASDAQ: ABAX) shares were also up, gaining 15 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
- [By Lisa Levin] Gainers Blink Charging Co. (NASDAQ: BLNK) shares climbed 31.68 percent to close at $7.19 on Wednesday. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million. Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares gained 24.15 percent to close at $3.29. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share. 21Vianet Group, Inc. (NASDAQ: VNET) shares surged 24 percent to close at $6.82. Check-Cap Ltd. (NASDAQ: CHEK) gained 20.25 percent to close at $4.87. HUYA Inc. (NYSE: HUYA) shares surged 18.42 percent to close at $22.50 Abaxis, Inc. (NASDAQ: ABAX) rose 16.15 percent to close at $83.34. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash. Pain Therapeutics, Inc. (NASDAQ: PTIE) shares jumped 16.07 percent to close at $10.62. Bilibili Inc. (NASDAQ: BILI) rose 16.04 percent to close at $14.11. Gemphire Therapeutics Inc. (NASDAQ: GEMP) gained 14.88 percent to close at $6.33. Phoenix New Media Limited (NYSE: FENG) rose 13.96 percent to close at $5.55. Daqo New Energy Corp. (NYSE: DQ) jumped 13.88 percent to close at $67.27 on Wednesday. Sea Limited (NYSE: SE) jumped 12.59 percent to close at $11.98 after reporting Q1 results. Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 12.01 percent to close at $5.13. Ascena Retail Group, Inc. (NASDAQ: ASNA) gained 11.93 percent to close at $3.19. Boot Barn Holdings, Inc. (NYSE: BOOT) climbed 11.66 percent to close at $24.52 on Wednesday after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance. Macy's, Inc. (NYSE: M) rose 10.83 percent to close at $33.17 after the company reported stronger-than-expected results for its first quarter and lifted guidance. ChemoCentryx, Inc. (NASDAQ: CCXI) gained 9.36 percent to close at $12.50. Canaccord Genuity initiated coverage on ChemoCentryx with a Buy rating. Biolinerx Ltd/S ADR (NASDAQ: BLRX)
Hot Canadian Stocks To Watch For 2019: CHS Inc(CHSCL)
Advisors' Opinion:- [By Joseph Griffin]
CHS (NASDAQ:CHSCL) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Friday.
Hot Canadian Stocks To Watch For 2019: U.S. Auto Parts Network, Inc.(PRTS)
Advisors' Opinion:- [By Max Byerly]
Media stories about U.S. Auto Parts Network (NASDAQ:PRTS) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. U.S. Auto Parts Network earned a news impact score of 0.16 on Accern’s scale. Accern also gave media headlines about the specialty retailer an impact score of 47.0744515537091 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
- [By Logan Wallace]
Media stories about U.S. Auto Parts Network (NASDAQ:PRTS) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. U.S. Auto Parts Network earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned media stories about the specialty retailer an impact score of 45.533280416614 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on U.S. Auto Parts Network (PRTS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment